Patents by Inventor Orest Olejnik

Orest Olejnik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070015694
    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.
    Type: Application
    Filed: October 19, 2005
    Publication date: January 18, 2007
    Inventors: James Chang, Orest Olejnik, Bruce Firestone
  • Publication number: 20060258617
    Abstract: Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.
    Type: Application
    Filed: July 27, 2006
    Publication date: November 16, 2006
    Inventors: Robert Lyon, Chin-Ming Chang, Joan-En Chang-Lin, James Chang, Orest Olejnik
  • Publication number: 20060241037
    Abstract: Disclosed are methods of preventing or treating a disease or adverse condition affecting the gastrointestinal tract of a mammal which comprise orally administering to a mammal a therapeutically effective amount of a prodrug of a proton pump inhibitor and an effective amount of a trefoil family factor peptide, mucoadhesive agent, or a combination thereof. Also disclosed are compositions which are suitable for use in a pharmaceutical dosage form. These compositions comprise a prodrug of a proton pump inhibitor, and also comprise a trefoil family factor peptide, a mucoadhesive component, or a combination thereof.
    Type: Application
    Filed: August 25, 2004
    Publication date: October 26, 2006
    Applicant: ALLERGAN INC.
    Inventors: Orest Olejnik, Peter Bakhit, Richard Graham, Jie Shen, Devin Welty, Diane Tang-Liu
  • Publication number: 20060100584
    Abstract: A needleless microprotrusion system for infusion of a medicament into a patient includes a plurality of microprotrusions having a length sufficient to penetrate a stratum corneum of the patient. A chemodenervating agent is disposed in a microprotrusions in a substrate is provided for supporting the microprotrusion and conforming the microprotrusions to a selected patient body part in order to enable uniform penetration of the microprotrusions into the corneum.
    Type: Application
    Filed: August 10, 2004
    Publication date: May 11, 2006
    Inventors: Orest Olejnik, Robert Lyons, Scott Gerondale
  • Publication number: 20060046958
    Abstract: Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence of hyperemia.
    Type: Application
    Filed: August 25, 2004
    Publication date: March 2, 2006
    Inventors: Peter Bakhit, Richard Graham, Orest Olejnik
  • Patent number: 6984628
    Abstract: This invention relates to compositions comprising trefoil family factor peptides which are useful in preventing or treating dry eye by topical administration of the composition to eye of the patient. One aspect of this invention relates to topical ophthalmic compositions comprising a trefoil factor family peptide, and preferably, a mucoadhesive component, as described herein. Another aspect of this invention relates to the use of these compositions to treat or prevent dry eye in a patient.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: January 10, 2006
    Assignee: Allergan, Inc.
    Inventors: Peter G. Bakhit, Orest Olejnik, Richard Graham
  • Publication number: 20050277698
    Abstract: Disclosed herein are aqueous solutions comprising a neuroprotective amine related to adamantane and a polyanionic polymer. Also disclosed herein are methods of treating glaucoma and methods of treating a disease or a condition wherein migration or proliferation of retinal pigment epithelium or glial cells causes or contributes to the cause of said disease or condition.
    Type: Application
    Filed: June 15, 2005
    Publication date: December 15, 2005
    Inventors: Patrick Hughes, Orest Olejnik
  • Publication number: 20050271705
    Abstract: Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
    Type: Application
    Filed: April 29, 2005
    Publication date: December 8, 2005
    Applicant: Allergan, Inc.
    Inventors: Patrick Hughes, Orest Olejnik, Glenn Huang, Joan-En Chang-Lin, Thierry Nivaggioli, JaneGuo Shiah, Michele Boix, Christian Sarrazin
  • Publication number: 20050244474
    Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.
    Type: Application
    Filed: April 29, 2005
    Publication date: November 3, 2005
    Applicant: Allergan, Inc.
    Inventors: Glenn Huang, Thierry Nivaggioli, Lon Spada, Hiroshi Sugimoto, Wendy Blanda, James Chang, Orest Olejnik
  • Publication number: 20050234018
    Abstract: Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.
    Type: Application
    Filed: April 15, 2004
    Publication date: October 20, 2005
    Applicant: ALLERGAN, INC.
    Inventors: Robert Lyons, Chin-Ming Chang, Joan-En Chang-Lin, James Chang, Orest Olejnik
  • Publication number: 20050232966
    Abstract: Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer.
    Type: Application
    Filed: April 15, 2004
    Publication date: October 20, 2005
    Applicant: ALLERGAN, INC.
    Inventors: Patrick Hughes, Orest Olejnik
  • Publication number: 20050181017
    Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.
    Type: Application
    Filed: January 19, 2005
    Publication date: August 18, 2005
    Applicant: Allergan, Inc.
    Inventors: Patrick Hughes, Orest Olejnik, Scott Whitcup, James Burke
  • Publication number: 20050147584
    Abstract: Disclosed herein are aqueous solutions comprising a neuroprotective amine related to adamantane and a polyanionic polymer. Also disclosed herein are methods of treating glaucoma and methods of treating a disease or a condition wherein migration or proliferation of retinal pigment epithelium or glial cells causes or contributes to the cause of said disease or condition.
    Type: Application
    Filed: January 5, 2004
    Publication date: July 7, 2005
    Inventors: Patrick Hughes, Orest Olejnik
  • Publication number: 20050142165
    Abstract: An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device. may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.
    Type: Application
    Filed: February 25, 2005
    Publication date: June 30, 2005
    Inventors: Orest Olejnik, Patrick Hughes, John Kent
  • Publication number: 20050031652
    Abstract: Compositions are provided including a neuroprotective amine related to adamantane and a polyanionic polymer which are well tolerated, non-toxic and/or result in reduced or fewer side effects. Methods are provided employing such compositions, for example, topically administering such compositions to human or animal eyes, for treating human or animal eyes.
    Type: Application
    Filed: September 14, 2004
    Publication date: February 10, 2005
    Applicant: Allergan, Inc.
    Inventors: Patrick Hughes, Orest Olejnik, Rhett Schiffman
  • Publication number: 20050026924
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: August 27, 2004
    Publication date: February 3, 2005
    Inventors: Richard Graham, Peter Bakhit, Orest Olejnik
  • Publication number: 20050026950
    Abstract: Methods including orally administering retinoid components to a human or animal to provide a substantially equivalent bioavailability of the retinoid component to the human or animal in the presence or absence of food in the human or animal.
    Type: Application
    Filed: July 29, 2004
    Publication date: February 3, 2005
    Applicant: Allergan, Inc.
    Inventors: Orest Olejnik, John Sefton
  • Publication number: 20050014691
    Abstract: This invention relates to compositions comprising trefoil family factor peptides which are useful in preventing or treating dry eye by topical administration of the composition to eye of the patient. One aspect of this invention relates to topical ophthalmic compositions comprising a trefoil factor family peptide, and preferably, a mucoadhesive component, as described herein. Another aspect of this invention relates to the use of these compositions to treat or prevent dry eye in a patient.
    Type: Application
    Filed: July 15, 2003
    Publication date: January 20, 2005
    Inventors: Peter Bakhit, Orest Olejnik, Richard Graham
  • Publication number: 20050009910
    Abstract: The present invention relates to method of sustained-delivery of an active drug to a posterior part of an eye of a mammal to treat or prevent a disease or condition affecting said mammal, wherein said disease or condition can be treated or prevented by the action of said active drug upon said posterior part of the eye, comprising administering an effective amount of an ester prodrug of the active drug subconjunctivally or periocularly. Preferably, the active drug is more than about 10 times as active as the prodrug. Other aspects of this invention deal with the treatment of certain diseases by the periocular or subconjunctival delivery of an ester prodrug, and certain pharmaceutical products containing ester prodrugs for periocular or subconjunctival administration.
    Type: Application
    Filed: July 10, 2003
    Publication date: January 13, 2005
    Inventors: Patrick Hughes, Orest Olejnik
  • Publication number: 20040219219
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Application
    Filed: May 21, 2004
    Publication date: November 4, 2004
    Applicant: ALLERGAN, INC.
    Inventors: Richard Graham, Peter Bakhit, Orest Olejnik